GHRP-6: the original growth hormone releasing peptide-6

GHRP-6 is a synthetic six-amino-acid peptide that activates the ghrelin receptor (GHSR-1a) and drives a pulse of growth hormone from the anterior pituitary. discovered in the 1980s in Cyril Bowers's lab and characterized through the 1990s, GHRP-6 helped reveal the existence of the ghrelin signaling axis years before ghrelin itself was identified.

what is GHRP-6?

GHRP-6 stands for "growth hormone releasing peptide-6", a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. it was developed as a tool to provoke GH release from the pituitary and ended up being one of the molecules that led directly to the discovery of the ghrelin receptor.

Ghigo and colleagues in European Journal of Endocrinology in 1997 reviewed the entire early GHRP literature and described the family of synthetic peptides as potent stimulators of somatotrope secretion that worked through a mechanism distinct from GHRH [1]. that paper captures the moment when researchers were certain a separate receptor existed for these compounds but had not yet cloned it.

the receptor turned out to be GHSR-1a, the growth hormone secretagogue receptor, and the endogenous ligand ghrelin was identified in 1999. in retrospect GHRP-6 was a synthetic ghrelin-mimetic before anyone knew ghrelin existed, which is part of why it has such a large historical footprint in endocrinology.

how does it work?

GHRP-6 binds GHSR-1a on pituitary somatotropes and on hypothalamic neurons, triggering a brisk pulse of growth hormone from the pituitary and stimulating appetite through arcuate-nucleus circuits. it also binds CD36, a scavenger receptor on macrophages and cardiomyocytes that is unrelated to the GH axis but is the basis for the cardiovascular research interest in GHRP-6.

on the pituitary side, the GH pulse from GHRP-6 is brisk and largely synergistic with GHRH: combining the two produces a much larger pulse than either alone. that synergy is the foundation of the diagnostic combination tests used to assess GH reserve in pituitary disease. unlike GHRH, GHRP-6 also raises cortisol and prolactin modestly, which is a tradeoff that newer secretagogues like ipamorelin were specifically designed to avoid.

the CD36 story is a separate strand of the literature. Demers and colleagues in Biochemical Journal in 2004 used photoaffinity cross-linking to map the GHRP binding site on CD36 to residues near Met169, distinct from the oxidized-LDL binding domain [2]. that finding is the molecular basis for the preclinical work showing GHRP-6 and related hexapeptides can modulate macrophage and cardiomyocyte biology independently of GH release.

a third strand is gastrointestinal motility. Qiu and colleagues in World Journal of Gastroenterology in 2008 reported that GHRP-6 accelerated gastric emptying in a diabetic mouse model of gastroparesis, an effect they attributed to GHSR activation on local cholinergic enteric nerves [3]. Kitazawa and colleagues in Gut in 2005 reported similar gastric-prokinetic effects for GHRP-6 and other ghrelin agonists using a breath-test paradigm [4].

what does the evidence show?

GHRP-6 has a thick mechanistic and short-term clinical literature but a thin long-term efficacy literature. the published evidence supports its acute effect on GH release, its synergy with GHRH, and several adjacent biological effects (appetite stimulation, gastric prokinesis, CD36 engagement). there are no large randomized controlled trials of GHRP-6 in body composition, athletic performance, or aging endpoints.

Sigalos and Pastuszak's 2018 review in Sexual Medicine Reviews consolidates the safety and efficacy data for GH secretagogues as a class, including GHRP-6, GHRP-2, hexarelin, and ipamorelin [5]. the review notes that GH secretagogues reliably raise GH and IGF-1 in the short term but that the long-term clinical evidence for body-composition or anti-aging endpoints in healthy adults is weak.

Lim and colleagues in BMB Reports in 2015 tested a GHRP-6-biotin conjugate on cultured myoblasts and reported increased expression of IGF-1 and collagen type I along with markers of muscle differentiation [6]. that is preclinical work in a dish, but it captures the through-line that explains GHRP-6's persistent appeal in muscle and recovery contexts.

regulatory and research status

GHRP-6 has no FDA approval for any indication. it has been used historically in research as a probe for GH secretion and as a pharmacological tool for studying the ghrelin receptor. its sale and labeling vary by country, but in the US it is treated as a research-use-only peptide.

GHRP-6 is on the World Anti-Doping Agency prohibited list under category S2 (peptide hormones, growth factors, related substances and mimetics) at all times. any competitive athlete in a WADA-tested sport should be aware that use is banned in and out of competition, and that ghrelin-receptor agonists are specifically flagged on the prohibited list.

safety considerations

in the published short-term human work, GHRP-6 has been generally well tolerated. the most consistent off-target effects are appetite stimulation, modest elevations in cortisol and prolactin alongside the GH pulse, and occasional facial flushing or transient blood-pressure changes. long-term safety in healthy adults using compounded research-peptide formulations has not been characterized.

the cortisol and prolactin elevation is the main reason GHRP-6 has largely been replaced in modern research by ipamorelin, which engages the same receptor but with a cleaner downstream profile. the practical consequence is that any "GH pulse without GH cost" framing of GHRP-6 needs to acknowledge those small but real off-target hormonal effects.

the appetite stimulation is biologically expected: GHRP-6 is acting at the ghrelin receptor, and ghrelin is the primary hunger hormone. in clinical contexts where weight gain is the goal (chemotherapy-induced anorexia, cachexia) that is a feature; in body-composition contexts it is a tradeoff.

where it fits in peptide research

GHRP-6 sits at the historical center of the GH secretagogue family alongside GHRP-2, hexarelin, and ipamorelin. all four hit GHSR-1a, but they differ in selectivity, pulse magnitude, and off-target profile. understanding GHRP-6 is the easiest path into understanding the rest of the family.

the most common comparison is with GHRP-2, which produces a stronger GH pulse and has been studied as a diagnostic agent for assessing GH reserve. hexarelin produces a similarly strong pulse and has the additional CD36-mediated cardiovascular interest that has driven much of its modern research life. ipamorelin is the cleanest member of the family with minimal cortisol or prolactin elevation; it is the secretagogue most often discussed in modern body-composition and recovery contexts.

the natural upstream comparison is with the GHRH-axis family, including tesamorelin, which acts through a different pituitary receptor and produces a different GH-pulse pattern. GHRH-axis and ghrelin-receptor agonists are not redundant; they sit on opposite sides of the pituitary "go" signal, which is why they have been studied in combination in diagnostic and research contexts. for the underlying biology of how peptides interact with receptors and feedback loops, see the free peptides and your body module.